Skip to main content
Equibles
PIII logo

PIII · P3 Health Partners Inc. · Metrics

Track PIII — free

Use PIII with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PIII.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.70 -0.05 (-1.82%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 9, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q are issued.”
View the 10-Q filed Nov 9, 2026
Market Cap
$19.61M
Shares
7.26M
Volume · Nov 13 29.47K Avg daily vol (3M) 30.21K

PIII metrics

76 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.70
Market cap
$19.61M

Price action

23 metrics
Price change (1W)
-32.5%
Price change (30D)
-34.8%
Price change (3M)
-74.7%
Price change (6M)
-76.1%
Price change (YTD)
-22.6%
Price change (1Y)
-61.4%
Trailing year
Price change (5Y)
—
52-week high
$16.47
52-week low
$1.52
Change from 52-week high
-83.6%
Change from 52-week low
+77.6%
Annualized volatility
221.7%
Annualized volatility (3M)
89.0%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
-1.2
RSI (14D)
28.5
Price vs SMA 50
-51.2%
Price vs SMA 200
-59.0%
Avg volume (3M)
30,209
Relative volume
1.0
Average dollar volume
$161,141

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
7.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.1×
reciprocal yield 1,594.4%
EV / EBITDA
35.7×
reciprocal yield 2.8%
EV / EBIT
—
P / sales
0.0×
reciprocal yield 7,926.0%
P / book
0.2
reciprocal yield 563.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-261.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.2×
reciprocal yield 588.2%
EV / revenue historical average (5Y)
0.3×
reciprocal yield 393.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-09

Profitability

9 metrics
Gross margin
—
Operating margin
-5.2%
Trailing 12 months
Net margin
-3.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$81.42M
Net income (TTM)
−$51.23M
Trailing 12 months
Diluted EPS (TTM)
$-23.32
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$337.93
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-30.19
EBITDA per diluted share (TTM)
$-11.85
Net income per diluted share (TTM)
$-18.30
Operating cash flow per diluted share (TTM)
$-29.62
Free cash flow per diluted share (TTM)
$-36.48
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.09
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+14.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.55B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+102.8%
Year over year · more shares
Revenue CAGR (3Y)
+11.6%
Revenue CAGR (5Y)
+24.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-46.4%
Return on assets
-7.6%
Debt / equity
1.1
Current ratio
0.5
EBITDA (TTM)
$2.73M
Free cash flow (TTM)
—
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
28.5
Return on invested capital
—
Trailing 12 months
Net cash
−$77.86M
Latest balance sheet
Cash & equivalents
$43.90M
Total assets
$669.72M
Total debt
$121.76M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$115.79M
Capital expenditures (TTM)
$119,000
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$2.60M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
20
13F filer change QoQ
+3
Institutional ownership
68.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+78.1%
Holder tenure
3.8
Price vs estimated holder cost
+25.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
35 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1832511 CUSIP 744413204 13F (30d) 27 filings 17 filers Visit website Investor relations